Sentry Investment Management LLC Boosts Holdings in Becton, Dickinson and Company (NYSE:BDX)

Sentry Investment Management LLC boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,400 shares of the medical instruments supplier’s stock after buying an additional 138 shares during the period. Sentry Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $338,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of BDX. WR Wealth Planners LLC lifted its holdings in shares of Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares during the last quarter. Clear Creek Financial Management LLC boosted its position in shares of Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC grew its stake in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division raised its holdings in shares of Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 45 shares during the period. Finally, Capital Advisors Ltd. LLC lifted its stake in shares of Becton, Dickinson and Company by 3.6% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock worth $326,000 after acquiring an additional 48 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Down 0.4 %

Becton, Dickinson and Company stock opened at $234.33 on Tuesday. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $259.92. The business has a fifty day moving average price of $237.52 and a 200-day moving average price of $235.10. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The stock has a market capitalization of $67.73 billion, a price-to-earnings ratio of 48.22, a PEG ratio of 1.76 and a beta of 0.43.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Evercore ISI lifted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Raymond James dropped their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.